• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Social Capital Suvretta Holdings Corp. III filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/14/22 10:34:36 AM ET
    $DNAC
    Get the next $DNAC alert in real time by email
    8-K
    false000185027000018502702022-11-142022-11-14

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 14, 2022

     

     

    PROKIDNEY CORP.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Cayman Islands

    001-40560

    98-1586514

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2000 Frontis Plaza Blvd.

    Suite 250

     

    Winston-Salem, North Carolina

     

    27103

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: ( 336) 999-7029

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A ordinary shares, $0.0001 par value per share

     

    PROK

     

    The Nasdaq Stock Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On November 14, 2022, ProKidney Corp. issued a press release to announce the financial results of ProKidney LP and its subsidiaries for the third quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1.

     

    The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

    Description

    99.1

    Press Release dated November 14, 2022

    104

    Cover Page Interactive Data File (embedded within Inline XBRL document)

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    PROKIDNEY CORP.

     

     

     

     

    Date:

    November 14, 2022

    By:

    /s/ James Coulston

     

     

     

    James Coulston
    Chief Financial Officer

     


    Get the next $DNAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Weger Mary

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    1/18/23 4:14:18 PM ET
    $DNAC

    SEC Form 4 filed by Weber Darin J.

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    1/18/23 4:13:35 PM ET
    $DNAC

    SEC Form 4 filed by Mckenzie Libbie Parker

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    1/18/23 4:12:58 PM ET
    $DNAC

    $DNAC
    SEC Filings

    View All

    SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. III

    424B3 - PROKIDNEY CORP. (0001850270) (Filer)

    1/20/23 6:52:24 AM ET
    $DNAC

    Social Capital Suvretta Holdings Corp. III filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - PROKIDNEY CORP. (0001850270) (Filer)

    1/19/23 4:18:53 PM ET
    $DNAC

    SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. III

    424B3 - PROKIDNEY CORP. (0001850270) (Filer)

    1/11/23 4:26:35 PM ET
    $DNAC

    $DNAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

    ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol "PROK" on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund Phase 3 study of REACT™PIPE is led by a $125 million investment from Social Capital, with an additional $50 million from existing ProKidney investors, approximately $30 million from Suvretta Capital's Averill strategy and the remaining $370 million from institutional investors and family offices Proceeds will fund ongoing Phase 2 and 3 development program for ProKidney's lead cell therapy candidate, REACT™, accelerate manufacturing scale-out, and ultimately prepare for its global commercial launch

    7/12/22 8:00:00 AM ET
    $DNAC

    Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders

    Social Capital Suvretta Holdings Corp. III ("SCS") today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney LP, a limited partnership organized under the laws of Ireland ("ProKidney"), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland, and the transactions contemplated thereby (the "Business Combination") on July 11, 2022 at 8:30 a.m., Eastern Time, physically at the offices of Wachtell, Lipton, Rosen & Katz located at 51 West 52nd Street, New York, New York 10019, and virtual

    7/8/22 7:36:00 PM ET
    $DNAC

    ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

    WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today published data from a patient study confirming the mechanistic action of its lead candidate REACT™ with cell marker analysis. "Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action with Cell Marker Analysis" by Joseph Stavas et. al. The paper, published in Kidney International Reports, describes observed improvements i

    6/23/22 8:00:00 AM ET
    $DNAC

    $DNAC
    Financials

    Live finance-specific insights

    View All

    Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III

    ProKidney offers a first-of-its-kind, patented disease-modifying autologous cell therapy for treatment of chronic kidney disease ("CKD") Lead product candidate, REACT®, has potential to slow, stabilize, and even reverse decline in kidney function, delaying the onset of dialysis and potentially delivering significant cost savings to healthcare systems globally REACT® has received Regenerative Medicine Advanced Therapy ("RMAT") designation, as well as U.S. FDA and European Medicines Agency guidance, for its Phase 3 clinical program; Phase 3 trial launched in the United States on schedule in January 2022 Transaction values the combined company at an equity value of $2.64 billion post

    1/18/22 7:00:00 AM ET
    $DNAC
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNAC
    Leadership Updates

    Live Leadership Updates

    View All

    ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer

    WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced the appointment of Libbie Parker McKenzie, MD, FASN as Chief Medical Officer. "On behalf of our entire team, I am excited to welcome Libbie to ProKidney. Her deep clinical, pharmacovigilance and regulatory affairs expertise will be instrumental to our continued success as we work to advance the development of our lead program, REACT®," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "In a

    4/28/22 8:00:00 AM ET
    $DNAC

    ProKidney Appoints Todd C. Girolamo as General Counsel

    WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced the appointment of Todd C. Girolamo as General Counsel. "We are thrilled to welcome Todd to the ProKidney team in such an important role," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "His experience as both an attorney and capital markets professional will be important to our future success, as we move closer to becoming a public company through our proposed merger with SCS. I look forward to wor

    3/28/22 8:00:00 AM ET
    $DNAC

    $DNAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. III

    SC 13G - PROKIDNEY CORP. (0001850270) (Subject)

    9/12/22 5:17:13 PM ET
    $DNAC

    SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. III

    SC 13D - PROKIDNEY CORP. (0001850270) (Subject)

    7/22/22 4:39:52 PM ET
    $DNAC

    SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. III

    SC 13D - PROKIDNEY CORP. (0001850270) (Subject)

    7/22/22 4:34:01 PM ET
    $DNAC